Loading clinical trials...
Loading clinical trials...
A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial With a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients Aged 10-24 Years
Conditions
Interventions
Dapagliflozin
Dapagliflozin placebo
Locations
42
United States
Research Site
New Haven, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Gainesville, Florida, United States
Research Site
Homestead, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Boston, Massachusetts, United States
Start Date
June 22, 2016
Primary Completion Date
April 6, 2020
Completion Date
April 6, 2020
Last Updated
February 23, 2022
NCT07232537
NCT06815081
NCT06003153
NCT06278207
NCT07051005
NCT07296484
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions